The Canada IBD market is estimated to grow significantly at a CAGR of around 5.2% during the forecast period. Rising prevalence and incidence of IBD across the country is the major driving factor for the market. Canada has among the highest reported prevalence and incidence rates of IBD across the globe. As per CCC, in 2018, nearly 270,000 Canadians were living with IBD, of which 135,000 individuals with Crohn’s disease, 120,000 with ulcerative colitis, and 15,000 with IBD type unclassified (IBD-U). CCC further estimates that seven out of every 1,000 Canadians has IBD. Moreover, by 2030, the number of people living with IBD is expected to rise to over 400,000, or nearly 1% of the population. The highest reported incidence of IBD is in Nova Scotia at 54.6 per 100,000 new cases per year, and the lowest is in British Columbia at 18.7 per 100,000 people per year. The incidence of IBD in Alberta, Manitoba, Ontario, Quebec, and Saskatchewan are similar, ranging from 21.6 to 28.3 per 100,000 people per year.
To Request a Sample of our Report on Canada Inflammatory Bowel Disease (IBD) Market: https://www.omrglobal.com/request-sample/canada-ibd-inflammatory-bowel-disease-market
Canada IBD market is segmented on the basis of disease type, diagnostics, and therapeutics. Canada IBD market is segmented on the basis of disease type into ulcerative colitis and Crohn’s disease. Crohn’s disease segment is estimated to dominate the market. The growth of the segment is attributed to the comparatively higher incidence of Crohn’s disease than ulcerative colitis. On the basis of diagnostics, the market segmented into blood and stool, endoscopies, ultrasound, and X-rays. Endoscopy is a conventional diagnostic method that is widely being used for the diagnosis of IBD and having a considerable share in the market. The therapeutics segment is further segmented into anti-inflammatory drugs and surgery. There is a range of anti-inflammatory drugs used for the treatment of IBD, such as immunosuppressants (methotrexate, ciclosporin and azathioprine), steroids and biological drugs. These are usually the first step in the treatment of IBD.
(Get 15% Discount on Buying this Report)
A full Report of Canada Inflammatory Bowel Disease (IBD) Market is Available @ https://www.omrglobal.com/industry-reports/canada-ibd-inflammatory-bowel-disease-market
Canada IBD Market Segmentation
By Disease Type
- Ulcerative Colitis
- Crohn’s Disease
By Diagnostics
- Blood and Stool Tests
- Endoscopies,
- Ultrasound
- X-Ray
By Therapeutics
- Surgery
- Anti- Inflammatory Drug Administration
- Steroids
- Immunosuppressant
- Biological Drugs
- Amino salicylates
- Others
Company Profiles
- Abbott Laboratories
- AbbVie Inc.
- Accesa Labs
- Boehringer Ingelheim International GmbH
- Celgene Corp.
- Eli Lilly and Co.
- Johnson & Johnson Services Inc.
- Laboratory Corporation of America Holdings
- Pfizer Inc.
- Sanofi S.A.
- Takeda pharmaceutical Co., Ltd.
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
